title: The effect of dosing regimen on the pharmacokinetics of risedronate.
abstract: OBJECTIVE
  To examine the effect of timing of a risedronate dose relative to food intake on the rate and extent of risedronate absorption following single-dose, oral administration to healthy male and female volunteers.
  
  
  METHODS
  A single-dose, randomized, parallel study design was conducted with volunteers assigned to four treatment groups (31 or 32 subjects per group, 127 subjects total). Each subject was orally administered 30 mg risedronate. Group 1 was fasted for 10 h prior to and 4 h after dosing (fasted group); Groups 2 and 3 were fasted for 10 h and were dosed 1 and 0.5 h, respectively, before a high-fat breakfast; and Group 4 was dosed 2 h after a standard dinner. Blood and urine samples were collected for 168 h after dosing. Pharmacokinetic parameters were estimated by simultaneous analysis of risedronate serum concentration and urinary excretion rate-time data.
  
  
  RESULTS
  Extent of risedronate absorption (AUC and Ae ) was comparable (P=0.4) in subjects dosed 2 h after dinner and 0.5 h before breakfast; however, a significantly greater extent of absorption occurred when risedronate was given 1 or 4 h prior to a meal (1.4- to 2.3-fold greater). Administration 0.5, 1, or 4 h prior to a meal resulted in a significantly greater rate of absorption (Cmax 2.8-, 3.5-, and 4.1-fold greater, respectively) when compared with 2 h after dinner.
  
  
  CONCLUSIONS
  The comparable extent of risedronate absorption when administered either 0.5-1 h before breakfast or 2 h after an evening meal support previous clinical studies where risedronate was found to have similar effectiveness using these dosing regimens. This flexibility in the timing of risedronate administration may provide patients an alternative means to achieve the desired efficacy while maintaining their normal daily routine.
authors.affiliation: Procter & Gamble Pharmaceuticals, Mason, Ohio, USA.
authors.forename: D Y
authors.initials: DY
authors.lastname: Mitchell
authors.forename: M A
authors.initials: MA
authors.lastname: Heise
authors.forename: K A
authors.initials: KA
authors.lastname: Pallone
authors.forename: M E
authors.initials: ME
authors.lastname: Clay
authors.forename: J D
authors.initials: JD
authors.lastname: Nesbitt
authors.forename: D A
authors.initials: DA
authors.lastname: Russell
authors.forename: C W
authors.initials: CW
authors.lastname: Melson
mesh_terms: D000042:Absorption; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005215:Fasting; D005260:Female; D018565:Food-Drug Interactions; D006801:Humans; D008297:Male; D000068296:Risedronic Acid; D012737:Sex Factors; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D000068296:Risedronic Acid; D012968:Etidronic Acid